Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 85 total PSOs listed by AHRQ.

Child Health Patient Safety Organization, Inc.
PSO Number: P0119
Component of Parent Org(s):
  • National Association of Children's Hospitals (N.A.C.H.)
Effective Date and Time of Initial Listing: October 12, 2011 12:01 AM ET
Street Address: 16011 College Blvd, Suite 250, Lenexa, Kansas 66219
PSO Phone Number: (913) 981-4118
Fax: (913) 766-7817
Point of Contact: Barbara Weis
Point of Contact Phone: (913) 981-4117
Point of Contact Email: barbara.weis@childrenshospitals.org (link is external)
Next biennial attestation for Two Contracts due between 10/12/2017 and 10/11/2019
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Emergency Consultants PSO, LLC (d/b/a ECI PSO, LLC)
PSO Number: P0069
Component of Parent Org(s):
  • ECI Healthcare Partners, LLC
Effective Date and Time of Initial Listing: June 17, 2009 12:01 AM ET
Street Address: 4075 Copper Ridge Drive, Traverse City, Michigan 49684
PSO Phone Number: (231) 946-6200
Fax: (231) 929-2412
Point of Contact: Mark A. Burnheimer Esq.
Point of Contact Phone: (231) 946-6200
Point of Contact Email: mab@bc-legal.com (link is external)
Next biennial attestation for Two Contracts due between 06/17/2019 and 06/16/2021
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No